Published in PLoS One on April 22, 2013
A beneficiary role for neuraminidase in influenza virus penetration through the respiratory mucus. PLoS One (2014) 0.86
Replication characteristics of swine influenza viruses in precision-cut lung slices reflect the virulence properties of the viruses. Vet Res (2013) 0.82
Distinct immune responses and virus shedding in pigs following aerosol, intra-nasal and contact infection with pandemic swine influenza A virus, A(H1N1)09. Vet Res (2016) 0.76
Discovery and Characterization of Diazenylaryl Sulfonic Acids as Inhibitors of Viral and Bacterial Neuraminidases. Front Microbiol (2017) 0.75
Rapid control of pandemic H1N1 influenza by targeting NKT-cells. Sci Rep (2016) 0.75
Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science (2009) 25.61
Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature (2009) 17.96
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2011) 14.93
In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature (2009) 14.59
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet (2005) 5.70
Influenza: old and new threats. Nat Med (2004) 5.35
Evidence for the natural transmission of influenza A virus from wild ducts to swine and its potential importance for man. Bull World Health Organ (1981) 4.20
Pathogenesis and transmission of the novel swine-origin influenza virus A/H1N1 after experimental infection of pigs. J Gen Virol (2009) 3.09
Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med (2012) 3.05
Genetic relatedness of hemagglutinins of the H1 subtype of influenza A viruses isolated from swine and birds. Virology (1983) 3.02
Replication, pathogenesis and transmission of pandemic (H1N1) 2009 virus in non-immune pigs. PLoS One (2010) 2.04
Preexisting immunity to pandemic (H1N1) 2009. Emerg Infect Dis (2009) 1.85
A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respir Viruses (2009) 1.42
Protection against a European H1N2 swine influenza virus in pigs previously infected with H1N1 and/or H3N2 subtypes. Vaccine (2003) 1.42
Serologic cross-reactivity with pandemic (H1N1) 2009 virus in pigs, Europe. Emerg Infect Dis (2010) 1.33
High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J Gen Virol (2009) 1.30
Experimental infection of pigs with the human 1918 pandemic influenza virus. J Virol (2009) 1.29
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther (2010) 1.26
A human case of swine influenza virus infection in Europe--implications for human health and research. Euro Surveill (2009) 1.19
Efficacy of vaccination of pigs with different H1N1 swine influenza viruses using a recent challenge strain and different parameters of protection. Vaccine (2001) 1.15
Novel reassortant of swine influenza H1N2 virus in Germany. J Gen Virol (2008) 1.12
Genetic and antigenic evolution of swine influenza viruses in Europe and evaluation of their zoonotic potential. Zoonoses Public Health (2009) 1.09
Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors. J Virol (2005) 1.09
Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin". J Infect Dis (1994) 1.09
Serological profiles after consecutive experimental infections of pigs with European H1N1, H3N2, and H1N2 swine influenza viruses. Viral Immunol (2006) 1.07
Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (δ-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine (2011) 1.05
Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One (2012) 1.00
Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006-2008. Influenza Other Respir Viruses (2009) 0.99
Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. Intervirology (2006) 0.98
Genetic characterization of a porcine H1N2 influenza virus strain isolated in Germany. Intervirology (2003) 0.98
Investigations of the efficacy of European H1N1- and H3N2-based swine influenza vaccines against the novel H1N2 subtype. Vet Rec (2003) 0.89
Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008. Med Microbiol Immunol (2011) 0.86
Swine influenza A vaccines, pandemic (H1N1) 2009 virus, and cross-reactivity. Emerg Infect Dis (2010) 0.85
Ongoing evolution of swine influenza viruses: a novel reassortant. Arch Virol (2008) 0.85
Molecular epidemiology of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 2001. Intervirology (2004) 0.83
Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999. Antiviral Res (2007) 0.80
Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med (2011) 4.46
The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res (2008) 4.04
Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol (2007) 1.96
Prevalence of PB1-F2 of influenza A viruses. J Gen Virol (2007) 1.88
Varicella vaccination in Europe - taking the practical approach. BMC Med (2009) 1.63
Phylogenetics, evolution, and medical importance of polyomaviruses. Infect Genet Evol (2009) 1.46
The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine (2011) 1.35
Novel [(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication. J Antimicrob Chemother (2005) 1.32
High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J Gen Virol (2009) 1.30
Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis (2008) 1.28
Prevalence of hepatitis E virus-specific antibodies in humans with occupational exposure to pigs. Med Microbiol Immunol (2011) 1.28
Sequencing of 21 varicella-zoster virus genomes reveals two novel genotypes and evidence of recombination. J Virol (2011) 1.16
Influenza neuraminidase: a druggable target for natural products. Nat Prod Rep (2011) 1.15
Current knowledge on PB1-F2 of influenza A viruses. Med Microbiol Immunol (2010) 1.12
Novel reassortant of swine influenza H1N2 virus in Germany. J Gen Virol (2008) 1.12
Molecular-based reclassification of the bovine enteroviruses. J Gen Virol (2006) 1.10
Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res (2004) 1.09
The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health (2007) 1.08
Expression of innate immune genes, proteins and microRNAs in lung tissue of pigs infected experimentally with influenza virus (H1N2). Innate Immun (2013) 1.06
Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses. Pediatr Infect Dis J (2013) 1.04
In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens. Planta Med (2008) 1.02
Isolation and molecular characterization of a second serotype of the encephalomyocarditis virus. Vet Microbiol (2012) 1.02
Genetic profile of an Oka varicella vaccine virus variant isolated from an infant with zoster. J Clin Microbiol (2004) 1.02
Quantitative structure-activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives. Inhibitors of human rhinovirus 2 replication. J Med Chem (2007) 1.02
Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem (2010) 1.01
Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. J Med Chem (2008) 1.01
The burden of varicella in Germany. Potential risks and economic impact. Eur J Health Econ (2004) 1.00
Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol (2008) 1.00
Per aspera ad astra: application of Simplex QSAR approach in antiviral research. Future Med Chem (2010) 0.98
Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. Intervirology (2006) 0.98
Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. J Antimicrob Chemother (2005) 0.97
Prevalence of BK virus subtype I in Germany. J Med Virol (2006) 0.97
Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test. Clin Vaccine Immunol (2012) 0.96
Evolution of four BK virus subtypes. Infect Genet Evol (2008) 0.95
Prevalence of antibodies to European porcine influenza viruses in humans living in high pig density areas of Germany. Med Microbiol Immunol (2013) 0.95
Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J Health Econ (2014) 0.94
The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev (2011) 0.94
Reassortants of the pandemic (H1N1) 2009 virus and establishment of a novel porcine H1N2 influenza virus, lineage in Germany. Vet Microbiol (2013) 0.94
Influenza A virus PB1-F2 gene. Emerg Infect Dis (2006) 0.93
Comparative analysis of DNA breakage, chromosomal aberrations and apoptosis induced by the anti-herpes purine nucleoside analogues aciclovir, ganciclovir and penciclovir. Mutat Res (2002) 0.91
N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells. J Virol (2006) 0.91
Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode. Future Med Chem (2011) 0.90
The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infect Dis (2014) 0.90
Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res (2003) 0.90
Seroprevalence of hepatitis E virus (HEV) in humans living in high pig density areas of Germany. Med Microbiol Immunol (2014) 0.90
Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2. Antivir Ther (2011) 0.90
Interferon-gamma-induced activation of nitric oxide-mediated antiviral activity of macrophages caused by a recombinant coxsackievirus B3. Viral Immunol (2005) 0.89
Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006. Antiviral Res (2009) 0.88
Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice. Med Microbiol Immunol (2003) 0.88
Quantitative multiplex real-time PCR for the sensitive detection of interferon beta gene induction and viral suppression of interferon beta expression. Cytokine (2003) 0.87
Influenza vaccination coverage rates in Germany a population-based cross-sectional analysis of the seasons 2002/2003 and 2003/2004. Med Klin (Munich) (2005) 0.87
Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19+ B lymphocytes. Viral Immunol (2010) 0.87
Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008. Med Microbiol Immunol (2011) 0.86
Poly(rC)-binding protein 2 interacts with the oligo(rC) tract of coxsackievirus B3. Biochem Biophys Res Commun (2007) 0.86
Interface dynamics explain assembly dependency of influenza neuraminidase catalytic activity. J Biomol Struct Dyn (2013) 0.86
2-amino-3-(oxirane-2,3-dicarboxamido)-propanoyl-valine, an effective peptide antibiotic from the epiphyte Pantoea agglomerans 48b/90. Appl Environ Microbiol (2009) 0.86
Age-related and regional differences in the prevalence of hepatitis E virus-specific antibodies in pigs in Germany. Vet Microbiol (2013) 0.85
Anti-coxsackievirus B3 activity of 2-amino-3-nitropyrazolo[1,5-a]pyrimidines and their analogs. Bioorg Med Chem Lett (2005) 0.85
Swine influenza A vaccines, pandemic (H1N1) 2009 virus, and cross-reactivity. Emerg Infect Dis (2010) 0.85
Ongoing evolution of swine influenza viruses: a novel reassortant. Arch Virol (2008) 0.85
Prevalence of antibodies to swine influenza viruses in humans with occupational exposure to pigs, Thuringia, Germany, 2008-2009. J Med Virol (2010) 0.84
New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3. Antiviral Res (2008) 0.84
Linkage map of protein-protein interactions of Porcine teschovirus. J Gen Virol (2005) 0.84
Antiviral effects of pan-caspase inhibitors on the replication of coxsackievirus B3. Apoptosis (2007) 0.84
Serological detection of specific IgG to varicella-zoster virus by novel ELISA based on viral glycoprotein antigen. Clin Lab (2009) 0.83
Genotyping of varicella-zoster virus strains after serial passages in cell culture. J Virol Methods (2007) 0.83
Low level myocardial parvovirus B19 persistence is a frequent finding in patients with heart disease but unrelated to ongoing myocardial injury. J Med Virol (2010) 0.83
Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis. Vaccine (2007) 0.83
Fatal outcome of herpes simplex virus type 1-induced necrotic hepatitis in a neonate. Med Microbiol Immunol (2006) 0.82
Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus. Antivir Ther (2011) 0.82
Detection of multiple human herpes viruses by DNA microarray technology. Mol Diagn (2004) 0.82
Simvastatin treatment showed no prophylactic effect in influenza virus-infected mice. J Med Virol (2013) 0.82
Resistance testing of clinical varicella-zoster virus strains. Antiviral Res (2011) 0.82
DSTP-27 prevents entry of human cytomegalovirus. Antimicrob Agents Chemother (2014) 0.82
Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. Antiviral Res (2003) 0.82
Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication. Arch Virol (2011) 0.82
Vaccination procedures against Coxsackievirus-induced heart disease. Expert Rev Vaccines (2003) 0.81
Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients. Med Microbiol Immunol (2012) 0.81
Apoptosis induced by (E)-5-(2-bromovinyl)-2'-deoxyuridine in varicella zoster virus thymidine kinase-expressing cells is driven by activation of c-Jun/activator protein-1 and Fas ligand/caspase-8. Mol Pharmacol (2003) 0.81
Impact of global warming on viral diseases: what is the evidence? Curr Opin Biotechnol (2008) 0.81
Co-expression of interleukin-2 by a bicistronic plasmid increases the efficacy of DNA immunization to prevent influenza virus infections. Intervirology (2006) 0.81
Significance of amino acid substitutions in the thymidine kinase gene of herpes simplex virus type 1 for resistance. Antiviral Res (2012) 0.81
QSAR analysis of [(biphenyloxy)propyl]isoxazoles: agents against coxsackievirus B3. Future Med Chem (2011) 0.80
Computer-guided approach to access the anti-influenza activity of licorice constituents. J Nat Prod (2013) 0.80